FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma

By afschroeder • July 20, 2025

Smyth EC, Kim KM, Rha SY, Wainberg ZA, Honeycutt H, Sommermann E, Ochiai A. FGFR2b protein overexpression: An emerging biomarker in gastric and gastroesophageal junction adenocarcinoma. Cancer Treat Rev. 2025 May 26;139:102971. doi: 10.1016/j.ctrv.2025.102971. Epub ahead of print. PMID: 40680491.

Tags: biomarkers, Fgfr2b, Fibroblast growth factor receptor, Fibroblast growth receptor 2b, gastric cancer, Hematology/Oncology, Publications, targeted therapy

Related Posts

Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation

Peters S, Meyer ML, André F, Argilés G, Azizi AA, Banerjee S, Burgers S, Curigliano G, Drago JZ, Fontana E, Garon EB, Klümper N, Le[...]

Tucatinib in Combination With Trastuzumab Deruxtecan in Patients With Previously Treated HER2+ Unresectable Locally Advanced or Metastatic Breast Cancer: An Open-Label Phase 2 Study

Modi S, Murthy RK, Chien AJ, Lin NU, McAndrew NP, Specht JM, Zelnak AB, Ramos J, Xie D, Ho J, Inoue JK, Carey LA, Hamilton[...]

Response to Letter to the Editor: ‘NALIRIFOX versus nab-paclitaxel and gemcitabine in older patients with treatment-naive metastatic pancreatic cancer: a subgroup analysis of the pivotal NAPOLI 3 trial’

Macarulla T, Cid RP, Womack MS, Gracian AC, Zervoudakis A, Hatoum H, Chung V, Patel A, Paulson AS, Pant S, O'Reilly EM, Hubner RA, Van[...]